FindTrial
Sign In

Devimistat

DRUG2 trials

Sponsors

Northwestern University, University of Michigan Rogel Cancer Center

Conditions

Advanced Biliary Tract CarcinomaAdvanced Colorectal CarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Lung AdenocarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Urothelial Carcinoma

Phase 1

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas
WithdrawnNCT05926206
University of Michigan Rogel Cancer CenterMetastatic Pancreatic Adenocarcinoma
Start: 2023-07-31End: 2027-01-31Updated: 2023-08-02

Phase 2

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RecruitingNCT05733000
Northwestern UniversityAdvanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma +30
Start: 2023-03-08End: 2030-03-04Target: 94Updated: 2023-03-10

Related Papers

Abstract CT224: Phase II open-label multi-cohort study evaluating CPI-613 (devimistat) in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemo-refractory solid tumors
Cancer Research2025-04-25